We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

43 hedge funds and large institutions have $91.8M invested in Protagonist Therapeutics in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

8% more funds holding

Funds holding: 40 → 43 (+3)

0.46% more ownership

Funds ownership: 47.7% → 48.16% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less capital invested

Capital invested by funds: $103M → $91.8M (-$10.8M)

Holders
43
Holders Change
+3
Holders Change %
+7.5%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
18
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.28M
2
SAM
Senzar Asset Management
New York
+$2.92M
3
Millennium Management
Millennium Management
New York
+$2.16M
4
EAM
Eventide Asset Management
Massachusetts
+$1.34M
5
BlackRock
BlackRock
New York
+$918K

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$8.15M
2
FCMI
Foresite Capital Management III
California
-$4.44M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.96M
4
SIM
Spark Investment Management
New York
-$403K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$65.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$28.6M +$110K +10,264 +0.4%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$23.3M +$4.28M +400,000 +24%
PI
3
Pharmstandard International
Luxembourg
$11.1M – – –
CAM
4
Cormorant Asset Management
Massachusetts
$5.66M -$1.96M -183,600 -27%
BlackRock
5
BlackRock
New York
$4.88M +$918K +85,821 +25%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.68M +$127K +11,881 +4%
SAM
7
Senzar Asset Management
New York
$3.09M +$2.92M +273,500 New
Millennium Management
8
Millennium Management
New York
$2.28M +$2.16M +201,712 New
EAM
9
Eventide Asset Management
Massachusetts
$1.41M +$1.34M +125,000 New
State Street
10
State Street
Massachusetts
$1.27M +$208K +19,411 +21%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.21M +$60.5K +5,662 +6%
PC
12
Polar Capital
United Kingdom
$1.13M +$802K +75,000 +300%
Northern Trust
13
Northern Trust
Illinois
$1.12M +$205K +19,159 +24%
Deutsche Bank
14
Deutsche Bank
Germany
$358K +$270K +25,210 +385%
GAMA
15
Graticule Asia Macro Advisors
New York
$328K -$29.9K -2,800 -9%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$313K +$15.8K +1,478 +6%
Renaissance Technologies
17
Renaissance Technologies
New York
$294K +$278K +25,989 New
TCIM
18
TIAA CREF Investment Management
New York
$264K +$40.8K +3,812 +19%
PP
19
PDT Partners
New York
$197K -$6.42K -600 -3%
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$188K +$13.9K +1,300 +8%
NCMW
21
Northern Capital Management (Wisconsin)
Wisconsin
$188K +$178K +16,665 New
TA
22
Teachers Advisors
New York
$183K +$72.3K +6,757 +71%
Charles Schwab
23
Charles Schwab
California
$150K – – –
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$114K +$108K +10,076 New
JP Morgan Chase
25
JP Morgan Chase
New York
$96K -$7.79K -729 -8%
1
2

PTGX Hedge Fund Activity: Q2 2017 in Review

43 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2017, worth a combined $91.8M — down 10% from $103M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PTGX positions and 4 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.28M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.15M sold.

  • 43 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2017, up from 40 in Q1 2017.
  • Funds reported $91.8M of Protagonist Therapeutics stock for Q2 2017, down 10% quarter-over-quarter.
  • 7 funds opened new Protagonist Therapeutics positions in Q2 2017 and 4 closed out, a net change of +3 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2017 was Adage Capital Partners, an estimated $4.28M added.
  • The largest Protagonist Therapeutics seller in Q2 2017 was RA Capital Management, an estimated $8.15M sold.

Based on aggregated 13F filings for Q2 2017.